The World Health Organization ranks major depressive disorder (MDD) and bipolar disorder (BD) as the first and fifth leading causes of years lived with disability (WHO [@CR237]), respectively, yet almost nothing is known about their pathogenesis. Because these conditions were not associated with gross brain pathology or with clear animal models for spontaneous, recurrent mood episodes, the availability of tools allowing noninvasive assessment of the human brain proved critical to elucidating their neurobiology. The recent development of neuroimaging technologies that permit in vivo characterization of the anatomical, physiological and neurochemical correlates of mood disorders thus has enabled significant advances toward illuminating the pathophysiology of these conditions. Notably, the results of neuroimaging studies and the post mortem studies that have been guided by neuroimaging results have given rise to neurocircuitry-based models in which both functional and structural brain pathology play roles in the development of mood disorders.

The symptomatology of the clinical syndrome shared by MDD and BD, namely the major depressive episode, implicates brain systems involved in the regulation of mood and emotional expression, reward processing, attention, motivation, stress responses, social cognition and neurovegetative function (e.g., sleep, appetite, energy, libido). For example, the diagnostic criteria for major depressive episodes (MDE) require persistence of either depressed mood or loss of interest and pleasure, in association with at least four of the following symptoms: inattention, fatigue, self-depreciating or suicidal thoughts, and disturbances of psychomotor activity, sleep, appetite and weight (APA [@CR4]). Anxiety symptoms also are prominent during MDE, and mood disorders commonly occur comorbidly with anxiety disorders such as panic disorder, social phobia, posttraumatic stress syndrome and obsessive--compulsive disorder (Kessler et al. [@CR116]). These comorbid syndromes generally worsen or improve in tandem with the severity of depressive symptoms. In BD episodes of depression occur alternately with manic or hypomanic episodes, during which the mood becomes euphoric and labile, the capacity for deriving pleasure increases, behaviors aimed at deriving pleasure increase, and energy, psychomotor activity, libido and self esteem become elevated. The symptomatology for mania thus implicates the same functional domains as those that characterize MDE, but in a manner that is phenomenologically antithetical.

In this paper, we consider the neurobiological bases of these clinical features by reviewing the abnormalities of brain structure and function that have been discovered in patients with mood disorders, and integrate these findings with information obtained about the function of putatively homologous brain systems in experimental animals. The data acquired from depressed patients that are presented below emphasize morphological, physiological and chemical data assessed via in vivo neuroimaging and post mortem neuropathological techniques. The neuroanatomical information contained within these studies are discussed by considering the prominent neural connections between implicated brain regions to construct circuit-based models that suggest mechanisms by which dysfunction can precipitate the behavioral signs and symptoms of affective disease. We propose specifically a neural model in which dysfunction within the MPFC and in the circuits that connect the MPFC to other cortical and limbic structures can account for the disturbances of emotional behavior, cognitive performance, neurotransmission, autonomic regulation and neuroendocrine responses that are associated with mood disorders.

Neurobiological correlates of mood disorders {#Sec1}
============================================

Despite many psychological and biological theories regarding the pathogenesis of mood disorders the etiologies of primary MDD and BD remain unknown. The spontaneous and perseverative nature of MDE symptoms and their responsiveness to antidepressant drugs suggest abnormal brain processes that underlie and maintain these conditions. Consistent with this expectation a variety of neurophysiological, neuropathological, and neurochemical abnormalities has been discovered in MDD and BD within the neural systems that modulate emotional behavior. None of these abnormalities has shown sufficient sensitivity and specificity to prove useful as a diagnostic test, however.

The variable presence and magnitude of such abnormalities in mood disorders likely reflects the heterogeneity encompassed within the MDD and BD syndromes with respect to pathophysiology and etiology. So long as psychiatric nosology depends on syndrome-based classifications, diagnoses for MDD will continue to encompass patients with a wide range of conditions that appear qualitatively and quantitatively distinct. This lack of precise and biologically verifiable definition of illness presumably contributes to the inconsistencies extant within the literature pertaining to neurobiological abnormalities associated with MDD, the high-placebo effect observed in antidepressant treatment trials, and the plethora of psychotherapeutic and biological treatment options that reportedly exert antidepressant effects (Drevets and Todd [@CR66]). Ultimately, the discovery of illness subtypes that are associated with specific biomarkers is expected to improve the effect size and reproducibility of research findings and therapeutic approaches.

Twin and other family studies indicate that genetic factors contribute substantially to the liability for developing MDD and BD, particularly in cases characterized by recurrent illness and early age-at-onset (Sullivan et al. [@CR211]; Drevets and Todd [@CR66]). The extant data suggest that the transmission of mood disorders involves complex interactions between multiple genes, each exerting relatively small effects on vulnerability. Several single nucleotide polymorphisms have been associated with increased risk for developing depression, although few of these findings are replicated. If confirmed in additional studies, these genetic markers would implicate neurotrophic, glutamatergic, cholinergic, serotonergic systems and intracellular signaling pathways in the pathogenesis of depression (Detera-Wadleigh and McMahon [@CR47]). The genetic data also support a role for acquired factors in disease expression (Sullivan et al. [@CR211]). For example, a gene--environment interaction was described in which a functional polymorphism in the serotonin transporter promoter region increased the risk for developing MDE specifically within the context of stress (Caspi et al. [@CR30]).

Stressful events are thought to constitute "acquired factors" that interact with genetic susceptibility in the development of mood disorders, although once the illness has been instantiated the potential links between stressors and subsequent MDE become progressively less evident (Drevets and Todd [@CR66]). Early in the course of illness, MDE commonly appear to follow severe, stressful life events, whereas patients with recurrent MDD or BD commonly report that their pattern of depressive symptoms is unexplained by stressful life situations. Nevertheless, even within the context of chronic depression, stressful life events can severely and persistently worsen both the severity of the current MDE and the course of illness with respect to lowering the mood baseline to which patients return between episodes (many patients with MDD and BD develop progressive worsening of illness with failure to return to the premorbid level of mood and function). This downward trajectory is intensified by the problem that the psychosocial impairment associated with MDE often precipitates additional stressful events, such as job loss, scholastic failure and marital conflict or separation.

A variety of physiological and medical stressors also increase the risk for developing MDE. Notably the life-event most clearly associated with the development of depression and mania is the cessation of pregnancy, as the post-partum period constitutes the epoch of greatest risk for developing MDD or BD (Drevets and Todd [@CR66]). Some neurological disorders, medical conditions and pharmacological substances also increase the risk for developing MDE, providing clues about the neurobiological systems in which dysfunction may induce depressive symptoms. For example, Parkinson's disease (PD) is associated with a two- to fourfold increase in the risk for developing MDE relative to other similarly disabling conditions. In about one-half of cases, the MDE onset precedes the onset of motor manifestations in PD (Santamaria et al. [@CR192]). These findings led to hypotheses that degeneration of dopaminergic and/or serotonergic projections in PD impairs neural processes underlying reward processing and mood modulation, yielding depressive, anhedonic and anxiety symptoms.

Other medical diseases that increase the risk for depression or mania include endocrine disturbances (e.g., Cushing's syndrome), degenerative basal ganglia disorders (e.g., Huntington's or Wilson's Diseases), temporal lobe epilepsy, and structural lesions (tumors, infarcts, injury) involving the striatum, frontal lobe or mesiotemporal cortex (Drevets and Todd [@CR66]). Pharmacologic agents that may precipitate MDE include drugs which induce endocrine or neurochemical changes similar to those found in primary mood disorders. For example, administration of corticosteroids (e.g., prednisone) or monoamine depleting agents (e.g., reserpine) result in neurochemical changes that resemble, respectively, the hypercortisolemia and reduced monoamineregic neurotransmitter function evident in MDD, and also can induce MDE in susceptible individuals (Drevets and Todd [@CR66]).

Neural circuits affected by mood disorders {#Sec2}
------------------------------------------

Evidence from neuroimaging, neuropathological, and lesion analysis studies implicates brain networks that normally regulate the evaluative, expressive and experiential aspects of emotional behavior in the pathophysiology of mood disorders (Phillips et al. [@CR169]). These circuits include the limbic-cortical-striatal-pallidal-thalamic circuits (LCSPT), formed by connections between the orbital and medial prefrontal cortex (OMPFC), amygdala, hippocampal subiculum, ventromedial striatum, mediodorsal and midline thalamic nuclei and ventral pallidum (Ongür et al. [@CR162]). The LCSPT circuits initially were related to *emotional behavior* on the basis of their anatomical connectivity with visceral control structures that mediate emotional expression, such as the hypothalamus and periaqueductal gray (PAG) (Nauta and Domesick [@CR151]). They initially were implicated in the *pathophysiology of depression* by the observations that degenerative basal ganglia diseases and lesions of the striatum and orbital cortex increased the risk for developing MDE (Folstein et al. [@CR78]). Because these conditions affect synaptic transmission through the LCSPT circuitry in diverse ways, it appears that dysfunction that alters transmission through these circuits in various ways can produce the pathological emotional symptoms encompassed by the MDE criteria (Drevets et al. [@CR56]).

In addition to the LCSPT itself, neuroanatomical experiments in monkeys have shown that the orbital and medial prefrontal cortex is associated with two extended cortical circuits. One of these, which is mainly related to the central and lateral orbital areas ("the orbital prefrontal network"), includes sensory association areas such as visual associated areas in the inferior temporal cortex and somatic-sensory associated areas in the insula and frontal operculum, as well as olfactory and taste cortex (Ongür and Price [@CR163]; Saleem et al. [@CR189]). In addition to sensory integration, this system codes for affective characteristics of stimuli such as reward, aversion, and relative value. The other extended cortical system, which is primarily connected to the medial prefrontal cortex and a small region in the caudolateral orbital cortex (the "medial prefrontal network") includes the dorsomedial/ dorsal anterolateral prefrontal cortex (e.g., BA 9), the mid- and posterior cingulate cortex, a region in the anterior superior temporal gyrus and sulcus, and the entorhinal and posterior parahippocampal cortex (Kondo et al. [@CR120]; Saleem et al. [@CR189]). This system does not have substantial sensory connections, but has prominent connections with limbic structures and visceral control structures (hypothalamus and periaqueductal gray) (Ongür and Price [@CR163]). This is the visceromotor system that is particularly involved in introspective functions such as mood and emotion, and visceral reactions to emotional stimuli. It closely resembles the "default system" that has been defined in human functional imaging studies as a system of areas that become deactivated from a resting "default" condition in most tasks that involve external attention to objects or events outside the individual (e.g., Gusnard et al. [@CR248]; Fox et al. [@CR247]). Compatible with this hypothesis, pharmacological, neurosurgical, and deep brain stimulation treatments for mood disorders appear to suppress pathological activity within the second visceromotor network structures such as the subgenual anterior cingulate cortex (sgACC), amygdala and ventral striatum (Drevets et al. [@CR54]; Mayberg et al. [@CR138]; Drevets and Price [@CR62]; Van Laere et al. [@CR226]).Fig. 1Regions and anatomical projections that form the extended visceromotor network. The cytoarchitectonic subdivisions of the human orbital (*upper left*) and medial prefrontal cortical surfaces (*lower left*) are distinguished here as being predominantly in the visceromotor (*pink*) or sensory (*green*) networks described in (Ongür and Price [@CR163]). These portions of the figure are modified from Ongür et al. ([@CR162]), with the*lighter shade of pink* reflecting more recent work regarding the portions of the medial wall that share the connectional features of the visceromotor network. The area shown in*blue*, the sulcal portion of BA 47 \[47 s; which corresponds to orbital portion of Walker area 12 (i.e., 12o) of the monkey; see Fig. [2](#Fig2){ref-type="fig"}\], shares features of both the visceromotor and sensory networks. This region and the anterior (agranular) insula (*Ia*) continue into the lateral cortical wall, so are better viewed in the coronal sections shown in Ongür et al. [@CR162]). The major structures that receive efferent projections from the visceromotor component of the OMPFC are indicated on the right panel over the brain diagram. These include the posterior cingulate cortex, the anterior temporal cortex, and the entorhinal and parahippocampal cortex, all of which are implicated in the "default system" (Hsu and Price [@CR107]; Kondo et al. [@CR119], [@CR120]; Price [@CR172]; Saleem et al. [@CR190], [@CR189]). *C* cortex, *MD* mediodorsal nucleus of the thalamus, *PAG* periaqueductal gray; *PV* periventricular nucleus of the thalamusFig. 2Architectonic maps of the orbital (*upper and right-center panels*) and medial prefrontal cortical surfaces (*left-center panel*) of the macaque brain, modified from Carmichael and Price ([@CR25]). The *upper panel* shows the areas hypothesized to form the "sensory" network of the orbital cortex based upon their afferent connections with various sensory domains, which are indicated next to each set of regions. This sensory network projects into the "visceromotor" network (*middle panel*). This latter network shares extensive, reciprocal connections with the amygdala, periaqueductal gray and hypothalamus (shown in coronal sections at the lower right, center and left, respectively), areas which play major roles in organizing or mediating the endocrine, autonomic, and behavioral aspects of emotional behavior. The specific cytoarchitectonic areas of the visceromotor component of the orbitomedial PFC are color coded according to the specific nuclei of the amygdala and hypothalamus or the column of the PAG to which they predominantly project (Carmichael and Price [@CR26]; Ongür and Price [@CR160]; Floyd et al. [@CR75], [@CR76]). *Bvl* ventrolateral part of the basal nucleus of the amygdala, *Ce* central nucleus of the amygdala, *DH* dorsal hypothalamic area, *LH* lateral hypothalamic area, *MH* medial hypothalamic area; *dlPAG*, *lPAG*, *vlPAG* dorsolateral, lateral, and ventrolateral columns of the PAG, respectively

The extended visceromotor network also has been implicated by neuroimaging studies of pathological anxiety syndromes that occur comorbidly with MDD and BD (Charney and Drevets [@CR33]). Although combinations of depressive and anxiety syndromes are classified by the current diagnostic nomenclature as a mood disorder plus a comorbid anxiety disorder, researchers expect that they reflect dysfunction from a single etiology, which alters emotion regulation within the visceromotor network. Consistent with this expectation, antidepressant drugs are the first-line treatments for both depressive and anxiety disorders.

### Brain structural abnormalities in mood disorders {#Sec3}

Patients with mood disorders show abnormalities of morphology or morphometry in many visceromotor network structures (Drevets and Price [@CR62]). The extent or prevalence of these abnormalities depends partly on clinical characteristics such as age-at illness-onset, capacity for developing mania or psychosis, and evidence for familial aggregation of illness. For example, elderly MDD subjects with late-onset depression show an increased prevalence of neuroimaging correlates of cerebrovascular disease, relative both to age-matched, healthy controls and to elderly depressives with an early age-at depression-onset (Drevets et al. [@CR56]). Similarly, MDD and BD cases who have either psychosis (delusions and/or hallucinations) or a late-life illness-onset show nonspecific signs of atrophy, such as lateral ventricle enlargement that are absent in early-onset, nonpsychotic MDD cases.

Nevertheless, early-onset, nonpsychotic MDD and BD cases also consistently show volumetric abnormalities that are localized to some PFC, cingulate and temporal lobe structures (Table [1](#Tab1){ref-type="table"}). The most prominent volumetric abnormality reported to date has been a reduction in gray matter in the *left* anterior cingulate cortex (ACC) ventral to the corpus callosum *genu* (i.e., "subgenual") which is evident in MDD and BD with evidence of familial clustering or with psychotic features (Botteron et al. [@CR14]; Coryell et al. [@CR39]; Drevets et al. [@CR61]; Hirayasu et al. [@CR104]). Preliminary data suggest this volumetric reduction exists early in illness and in young adults at high familial risk for MDD (Botteron et al. [@CR14]; Hirayasu et al. [@CR104]).

Gray matter volume also is reduced in the orbital (BA 11, 47) and ventrolateral PFC (VLPFC; BA 45, 47) in MDD (Drevets and Price [@CR62]) and BD (Lyoo et al. [@CR130]) the frontal polar/dorsal anterolateral PFC (BA 9, 10) in MDD (Drevets et al. [@CR56]), and the posterior cingulate cortex and superior temporal gyrus in BD (Nugent et al. [@CR157]). In BD the peak difference in gray matter loss in the lateral orbital cortex was found in the sulcal BA47 cortex (Nugent et al. [@CR157]), a region that appears to correspond to an area which Ongür et al. proposed is related to the MPFC as part of the medial prefrontal network (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). In addition, white matter is decreased in the genu of the corpus callosum in both adults with MDD or BD and their high-risk child and adolescent offspring (particularly in females), and in the splenium of the corpus callosum in adults with MDD or BD.

Some studies also reported reductions in hippocampal volume in MDD, ranging in magnitude from 8 to 19%, although other studies did not replicate these differences (Drevets et al. [@CR56]). The discrepant results across studies may reflect clinical heterogeneity as one study reported that reduced hippocampal volume was limited to depressed women who suffered early-life trauma, Vythilingam et al. ([@CR233]) and others reported that hippocampal volume correlated inversely with time spent depressed (e.g., Sheline et al. [@CR201]). In addition, preliminary evidence suggests that volumetric reductions in the anterior subiculum/ventral CA1 region appeared specific to BD.

Elucidating the effect of such clinical variables may also prove helpful in resolving disagreements in the literature regarding the existence of morphometric abnormalities in the amygdala and striatum. In the amygdala, the volume has been reported to be increased in some studies but decreased in others in depressives relative to controls (Drevets et al. [@CR56]). In the striatum Husain et al. ([@CR241]) reported that the putamen was smaller in depressives than controls, and Krishnan et al. ([@CR244]) found a smaller caudate nucleus volume in depressives than controls. In a sample limited to elderly depressives, Krishnan et al. ([@CR245]) also reported smaller putamen and caudate volumes relative to controls. These findings were consistent with the post mortem study of Baumann et al. ([@CR10]), which found that caudate and accumbens area volumes were markedly decreased in both MDD and BD samples relative to control samples. Nevertheless, other studies found no significant difference in stiatal or pallidal volumes between younger MDD subjects and controls (Drevets et al. [@CR56]).

Conventional antidepressant drug treatment and symptom remission do not appear to alter the reductions in gray matter volume in the sgACC (Drevets et al. [@CR61]), but may arrest further gray matter decrements in the hippocampus (Sheline et al. [@CR201]). However, chronic lithium treatment, which exerts robust neurotrophic effects in animal models, has been associated with increasing gray matter volume toward normal in treatment responders in the sgACC and other PFC areas (Moore et al. [@CR143]).

Finally, consistent with evidence that the hypothalamic-pituitary-adrenal axis function is elevated in some mood-disordered subgroups, the pituitary and adrenal glands are reportedly enlarged in MDD. For example Krishnan et al. ([@CR243]) showed that MRI-based measures of cross-sectional area and volume of the pituitary were increased (by 34 and 41%, respectively) in depressives versus controls. This observation is consistent with evidence that the adrenal gland is also abnormally enlarged in MDD (reviewed in Drevets et al. [@CR56]), putatively due to chronically elevated stimulation of the adrenal cortex by ACTH.

### Neurophysiological imaging abnormalities in mood disorders {#Sec4}

Many of the regions where structural abnormalities are apparent in mood disorders also contain abnormalities of cerebral blood flow (CBF) and glucose metabolism (Table [1](#Tab1){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). In most of these structures, and particularly those which form the extended visceromotor network (see above), the basal activity appears increased in the depressed phase relative to the remitted phase of MDD. This pattern of differences has been demonstrated by longitudinal studies of depressed patients imaged before versus after treatment (e.g., Drevets et al. [@CR54]), or of remitted patients scanned before versus during depressive relapse (e.g., Neumeister et al. [@CR155]).Table 1Neuroimaging and histopathological abnormalities evident in the visceromotor network (Ongür et al. [@CR162]) in early-onset, recurrent major depressive disorder and/or bipolar disorderBrain regionGray matter volumeCell counts, cell markersGlucose metabolism, CBFDep versus ConDep versus ConDep versus ConDep versus RemDorsal medial/anterolateral PFC (BA9)↓↓↓↓Frontal polar C (BA 10)↓↓↓Subgenual anterior cingulate C↓↓↓/↓^a^↓Pregenual anterior cingulate C↓↓↓↓Orbital C/ventrolateral PFC↓↓↓↓Posterior cingulate↓↓↓Parahippocampal C↓↓ BD↓↓Amygdala↓/↑^b^↓ MDD↓↓Ventromedial striatum↓↓↓Hippocampus↓↓ BDn.s.n.s.Superior temporal G/temporopolar C↓↓Medial thalamus↓↓^a^In the subgenual anterior cingulate cortex the apparent reduction in CBF and metabolism in PET images of depressed subjects is thought to be accounted for by the reduction in tissue volume in the corresponding cortex, as after partial volume correction for the reduction in gray matter the metabolism appears increased relative to controls^b^The literature is in disagreement with respect to the amygdala volume in mood disorders. In MDD, the volume appears reduced in cases whose MDE show a chronic or intermit course*C* cortex, *Dep versus Con* unmedicated depressives versus healthy controls, *Dep versus Rem* unmedicated depressives versus themselves in either the medicated or unmedicated remitted phases, *G* gyrus, *n.s.* differences generally not significant, *PFC* prefrontal cortexEmpty cells indicate insufficient data. Modified from (Drevets [@CR53])Fig. 3Areas of abnormally increased physiological activity in familial MDD shown in images of unpaired *t* values, which were computed using a statistical parametric mapping approach to compare activity between depressives and controls (Drevets et al. [@CR67], [@CR61]). *Upper left* the positive *t* values in this sagittal section located 17 mm left of midline (*X* = −17) show areas were CBF is increased in depressives versus controls in the amygdala and medial (MED) orbital cortex (reproduced from Price et al. [@CR173]). *Upper right* positive *t* values in a sagittal section 41 mm left of midline (*X* = −41) show areas where CBF is increased in the depressives in the left ventrolateral PFC (VLPFC), lateral orbitofrontal C, and anterior insula (reproduced from Drevets et al. [@CR56]). *Lower right* positive *t* values in a coronal section located 19 mm posterior to the anterior commissure (*Y* = −19) shows an area where CBF is increased in the depressives in the left medial thalamus (reproduced from Drevets and Todd [@CR66]). *Lower left* coronal (31 mm anterior to the anterior commissure; *Y* = 31) and sagittal (3 mm left of midline; *X* = −3) sections showing negative voxel *t* values where glucose metabolism is decreased in depressives relative to controls. The reduction in activity in this prefrontal cortex (*PFC*) region located in the anterior cingulate gyrus ventral to the genu of the corpus callosum (i.e., subgenual) appeared to be accounted for by a corresponding reduction in cortex volume (Table [1](#Tab1){ref-type="table"}; reproduced from Drevets et al. [@CR61]). Anterior or left is to left

Nevertheless, the reduction in gray matter volume in some structures is sufficiently prominent to produce partial volume effects in functional brain images due to their relatively low spatial resolution, yielding complex relationships between physiological measures and depression severity. For example, relative to controls, depressed MDD and BD subjects show metabolic activity that appears *reduced* in the sgACC (Drevets et al. [@CR61]). However, when this volumetric deficit is taken into account by correcting the metabolic data for the partial volume averaging effect associated with the corresponding gray matter reduction (which have ranged in magnitude from about 20 to 50% across studies of MDD and BD), metabolism instead appears *increased* in the sgACC in the unmedicated-depressed phase and normal in the medicated-remitted phase (Drevets and Price [@CR62]). The volumetric reductions in the orbital cortex and VLPFC may also contribute to the complexity of relationships observed between metabolism and illness severity, as metabolism appears elevated in depressed samples of mild-to-moderate severity, but reduced in more severe, treatment refractory cases (Drevets et al. [@CR67]; Ketter et al. [@CR242]).

Although the pattern of activity in the extended visceromotor network generally is one in which metabolism is elevated during the depressed relative to the remitted phases, the relationship between physiological activity and symptom severity differs in valence across some structures, compatible with preclinical evidence that distinct MPFC structures are involved in opponent processes with respect to emotional behavior (Vidal-Gonzalez et al. [@CR228]). Regions where metabolism correlates positively with depression severity include the amygdala, sgACC and ventromedial frontal polar cortex (Drevets and Price [@CR62]; Hasler et al. [@CR100]). Metabolism and flow decrease in these regions as a common functional anatomical effect of both antidepressant drug treatment and deep brain stimulation of the sgACC or anterior capsule (Mayberg et al. [@CR138]; Drevets et al. [@CR54]; Van Laere et al. [@CR226]; Mayberg et al. [@CR137]), despite the diverse mechanisms underlying these treatments. Conversely, in recovered MDD cases who experience depressive relapse under experimental conditions involving serotonin or catecholamine depletion, the metabolic activity increases in these regions as the depressive symptoms return (Neumeister et al. [@CR155]; Hasler et al. [@CR100]) although the elevation of left amygdala activity during serotonin depletion-induced relapse was limited to homozygotes for the long allele of the serotonin transporter promoter region length polymorphism (5HTT LPR) (Neumeister et al. [@CR154]).

In some regions abnormalities of physiological activity appear specific to clinically defined subtypes of mood disorders. For example, in the amygdala, abnormal elevations of resting metabolism can be seen in depressed samples categorized as having BD, familial pure depressive disease (FPDD), MDD-melancholic type, or MDD which is responsive to a night of total sleep deprivation (reviewed in Drevets [@CR51]). In such cases, amygdala metabolism decreases toward normative levels during effective antidepressant treatment (Drevets et al. [@CR54]).

In contrast, a broader range of depressed subjects appears to show abnormal hemodynamic responses in the amygdala to emotional stimuli (as detailed below under the section, *Emotional Processing Bias*). For example, the hemodynamic responses of the left amygdala were smaller in magnitude in depressed children (Thomas et al. [@CR220]) and adults (Drevets [@CR52]) while viewing fearful faces, and prolonged in duration in depressed adults while viewing sad words (Siegle et al. [@CR204]). In contrast, MDD cases showed increased hemodynamic activity relative to controls in the left amygdala in response to fearful (Sheline et al. [@CR200]) and sad faces (Fu et al. [@CR80]) presented using backward-masking technique (such that subjects were explicitly aware only of having seen a face with a neutral expression). This exaggerated left amygdala response was attenuated following successful antidepressant pharmacotherapy.

In the accumbens area, medial thalamus and posterior cingulate cortex metabolism is abnormally elevated in the depressed phase of MDD and BD (Drevets et al. [@CR54], [@CR56]). In fMRI studies the regional hemodynamic responses are attenuated in the ventral striatum in reward-processing tasks, and in both the ventral striatum and the posterior cingulate in tasks involving negative feedback (e.g., Knutson et al. [@CR118]).

### Neuropathological correlations in mood disorders {#Sec5}

Most of the regions where MRI studies demonstrated volumetric abnormalities in mood disorders also have been shown to contain histopathological changes or gray matter volumetric reductions in post mortem studies of MDD and BD. For example, reductions of gray matter volume, thickness or wet weight have been reported in the subgenual ACC, posterolateral orbital cortex, and ventral striatum in MDD and/or BD subjects relative to controls (Baumann et al. [@CR10]; Bowen et al. [@CR15]; Ongür et al. [@CR161]; Rajkowska et al. [@CR177]), and greater decrements in volume following fixation (implying a deficit in the neuropil) were demonstrated in the hippocampus in MDD (Stockmeier et al. [@CR209]). The histopathological correlates of these abnormalities included reductions in glial cells with no equivalent loss of neurons, reductions in synapses or synaptic proteins, elevations in neuronal density, and reductions in neuronal size in MDD and/or BD samples (Rajkowska et al. [@CR177]; Ongür et al. [@CR161]; Cotter et al. [@CR41], [@CR40]; Eastwood and Harrison [@CR68], [@CR69]; Uranova et al. [@CR225]). Reductions in glial cell counts and density, and/or glia-to-neuron ratios additionally were found in MDD subjects versus controls in the pregenual ACC (pgACC \[BA24\]) (Cotter et al. [@CR41]), the dorsal anterolateral PFC (BA9) (Cotter et al. [@CR40]; Uranova et al. [@CR225]) and the amygdala (Bowley et al. [@CR16]; Hamidi et al. [@CR99]). Finally, the mean size of neurons was reduced in the dorsal anterolateral PFC (BA 9) in MDD subjects relative to controls (Rajkowska et al. [@CR177]), and the density of nonpyramidal neurons was decreased in the ACC and hippocampus in BD (Benes et al. [@CR11]; Todtenkopf et al. [@CR222]), and in the dorsal anterolateral PFC (BA9) of MDD (Rajkowska et al. [@CR178]). Reductions in synapses and synaptic proteins were evident in BD subjects in the hippocampal subiculum/ventral CA1 region (Eastwood and Harrison [@CR68]; Rosoklija et al. [@CR185]), and the expression of multiple genes involved in axonal growth/synaptic function was reduced in the middle temporal cortex in MDD subjects (Aston et al. [@CR5]). Notably, in several of these studies, the decreases were largely accounted for by differences in the left hemisphere (e.g., Bowley et al. [@CR16]; Hamidi et al. [@CR99]; Bowen et al. [@CR15]; Ongür et al. [@CR161]).

The glial type that specifically differed between MDD and control samples in many of these studies was the oligodendrocyte (e.g., Uranova et al. [@CR225]; Hamidi et al. [@CR99]). Oligodendroglia are best characterized for their role in myelination, and the reduction in oligodendrocytes may conceivably arise secondary to an effect on myelin, either through demyelination, abnormal development, or atrophy in the number of myelinated axons. Notably, the myelin basic protein concentration was found to be decreased in the frontal polar cortex (BA 10) (Honer et al. [@CR105]), and the expression of genes related to oligodendrocyte function (i.e., genes which encoded structural components of myelin, enzymes involved in the synthesis of myelin constituents or in the regulation of myelin formation, transcription factors regulating other myelination-related genes, or factors involved in oligodendrocyte differentiation) was decreased in the middle temporal gyrus in MDD subjects relative to controls (Aston et al. [@CR5]). Compatible with these data, the myelin staining was decreased in the deep white matter of the dorsolateral PFC in MDD and BD subjects (Regenold et al. [@CR181]), and the white matter volume of the genual and splenial portions of the corpus callosum were abnormally reduced in MDD and BD (e.g., Brambilla et al. [@CR18]). These regions of the corpus callosum also were smaller in child and adolescent offspring of women with MDD who had not yet developed a mood disorder, relative to age-matched controls, suggesting that the reduction in white matter in MDD reflects a developmental defect that exists prior to illness onset (Martinez et al. [@CR134]). These observations are compatible with evidence that the glial cell loss in mood disorders includes a reduction in myelinating oligodendrocytes.

Another observation that supports this hypothesis is that several reports of deficits in glia in the cerebral cortex depended upon laminar analysis, with the greatest effects in layers III, V, and VI (Cotter et al. [@CR41], [@CR40]; Rajkowska et al. [@CR177], [@CR176]; Uranova et al. [@CR225]; Vostrikov et al. [@CR229]). The intracortical plexuses of myelinated fibers known as "Bands of Baillarger" are generally concentrated in layers III and V. The size of these plexuses varies across cortical areas, so if the oligodendrocytes related to these plexuses were affected, different areas would be expected to show greater or lesser deficits. Layer VI in particular has a relatively large component of myelinated fibers running between the gray and white matter.

Finally, satellite oligodendrocytes also were implicated in the pathophysiology of mood disorders by electron microscopic study of the PFC in BD which revealed decreased nuclear size, clumping of chromatin and other types of damage to satellite oligodendrocytes, including indications of both apoptotic and necrotic degeneration (Uranova et al. [@CR224]; Vostrikov et al. [@CR229]). Satellite oligodendrocytes are immunohistochemically reactive for glutamine synthetase, suggesting they function like astrocytes to take up synaptically released glutamate for conversion to glutamine and cycling back into neurons (D'Amelio et al. [@CR44]).

In other brain regions, reductions in astroglia have been reported by post mortem studies of mood disorders. In the frontal cortex one study found that four forms of the astrocytic product, glial fibrillary acidic protein (GFAP), were decreased in mood-disordered subjects relative to controls, although it was not determined whether this decrement reflected a reduction in the astrocyte density or the GFAP expression (Johnston-Wilson et al. [@CR114]). However, another study which used immunohistochemical staining for GFAP did not find significant differences in cortical astrocytes between controls, and MDD or BD cases (Webster et al. [@CR235]). Other studies also did not find differences in GFAP between mood-disorder cases and controls (reviewed in Cotter et al. [@CR42]).

Factors that may conceivably contribute to a loss of oligodendroglia in mood disorders include the elevated glucocorticoid secretion and glutamatergic transmission evident during depression and mania. Glucocorticoids affect both glia and neurons (Cheng and de Vellis [@CR34]) and elevated glucocorticoid concentrations and repeated stress decrease the proliferation of oligodendrocyte precursors (Alonso [@CR1]; Banasr and Duman [@CR7]). Moreover, oligodendrocytes express AMPA and kainate type glutamate receptors, and are sensitive to excitotoxic damage from excess glutamate (Dewar et al. [@CR48]; Matute et al. [@CR135]; McDonald et al. [@CR139]). The targeted nature of the reductions in gray matter volume and glial cells to specific areas of the limbic-cortical circuits that show increased glucose metabolism during depressive episodes is noteworthy given the evidence reviewed below that the glucose metabolic signal is dominated by glutamatergic transmission.

### Correlations with rodent models of chronic and repeated stress {#Sec6}

The putative role of stress in precipitating MDE has promoted the development of rodent stress models to facilitate investigations of the neurobiological correlates of human mood disorders. In regions that appear homologous to the areas where gray matter reductions are evident in depressed humans (i.e., medial PFC, hippocampus), repeated stress results in dendritic atrophy and reductions in glial cell counts or proliferation in rodents (Banasr and Duman [@CR7]; Czeh et al. [@CR43]; McEwen and Magarinos [@CR140]; Wellman [@CR236]; Radley et al. [@CR175]; Conrad et al. [@CR37]). In the basolateral amygdala (BLA), chronic, unpredictable stress also produced dendritic atrophy, but chronic immobilization stress instead *increased* dendritic branching (Banasr and Duman [@CR7]; Vyas et al. [@CR232], [@CR230]), suggesting that the effect of chronic immobilization stress on dendritic remodeling is regionally specific (Conrad et al. [@CR37]).

Dendritic atrophy presumably would be reflected by a decrease the volume of the neuropil, which occupies most of the gray matter volume. The similarities between the histopathogical changes that accompany stress-induced dendritic atrophy in rats and those found in humans suffering from depression thus have led to hypotheses that homologous processes underlie the reductions in gray matter volume in hippocampal and PFC structures in MDD and BD (McEwen and Magarinos [@CR140]). In rats the stress-induced dendritic atrophy in the medial PFC was associated with impaired modulation (i.e., extinction) of behavioral responses to fear-conditioned stimuli (Izquierdo et al. [@CR109]). The observation that such changes influence emotional expression are noteworthy in light of evidence that volumetric reductions in humans with mood disorders are associated with more severe and chronic pathological mood episodes. Moreover, when rats were subjected to repeated stress beyond 4 weeks, the dendritic atrophy could be reversed by lithium administration (McEwen and Magarinos [@CR140]). The differential effects of these drugs on dendritic atrophy in stressed rats thus resemble their effects on sgACC volume in humans with BD (Moore et al. [@CR143]; Drevets et al. [@CR61]; Drevets and Savitz [@CR64]).

These dendritic reshaping processes depend on interactions between the increased *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor stimulation and glucocorticoid secretion associated with repeated stress (McEwen and Magarinos [@CR140]). Elevations of glutamate transmission and cortisol secretion in mood disorders also may contribute to reductions in gray matter volume and synaptic markers by inducing dendritic atrophy in some brain structures, as the depressive subtypes (e.g., BD, FPDD) who show regional reductions in gray matter volume also show evidence of increased cortisol secretion and glutamate transmission (Drevets et al. [@CR60]). Subjects with FPDD or familial BD also show elevations of glucose metabolism, which largely reflects glutamate transmission (see below), in the medial and orbital PFC, amygdala, ventral striatum, and cingulate cortex regions that show reductions in gray matter volume and cellular elements. The findings that gray matter reductions appear to occur specifically in regions that show hypermetabolism during depression thus raise the possibility that excitatory amino acid transmission plays a role in the neuropathology of mood disorders. In many of the regions where glucose metabolism is increased in the depressed phase relative to the remitted phase, reductions in cortex volume and/or histopathological changes have been found in in vivo MRI studies and/or post mortem studies of MDD and/or BD.

Neurochemical systems implicated in depression {#Sec7}
----------------------------------------------

Of the neurochemical systems that modulate neural transmission within the visceromotor network, mood disorders have been associated with abnormalities of serotonergic, dopaminergic, noradrenergic, cholinergic, glutamatergic, GABA-ergic, glucocorticoid and peptidergic \[e.g., corticotrophin releasing factor (CRF)\] function. Agents that impact monoamineregic neurotransmitter systems particularly have received attention because most antidepressant drugs exert their primary pharmacological actions through these systems. However, the delayed onset of antidepressant effects (generally lagging the initiation of treatment by about 3 weeks) suggest that secondary mechanisms involving changes in gene expression and/or synaptic plasticity may underlie the therapeutic mechanisms of these drugs. The neuropharmacological mechanisms hypothesized to serve as final common pathways for antidepressant responses include: (1) increases in the gene expression of brain derived neurotrophic factor (BDNF) and other neurotrophic/neuroprotective factors in the hippocampus and PFC (Manji et al. [@CR133]; Santarelli et al. [@CR193]); (2) enhancement of postsynaptic serotonin type 1A (5-HT~1A~) receptor function (Haddjeri et al. [@CR98]; Chaput et al. [@CR32]); (3) attenuation of the sensitivity or transmission of NMDA-glutamatergic receptors (Krystal et al. [@CR121]; Paul and Skolnick [@CR166]).

### Glutamatergic and GABA-ergic systems {#Sec8}

The function of glutamate and γ-amino-butyric acid (GABA) appears altered in mood disorders. Early studies reported that GABA concentrations were abnormally decreased in the plasma and cerebrospinal fluid (CSF) in MDD subjects (reviewed in Hasler et al. [@CR101]). In contrast, post mortem studies of the NMDA receptor complex in suicide victims found evidence suggesting that glutamatergic transmission had been increased in the PFC antemortem, and implicated disturbances in glutamate metabolism, NMDA, and mGluR1,5 receptors in depression and suicide (Paul and Skolnick [@CR166]). Moreover, antidepressant and mood-stabilizing drugs which have diverse primary pharmacological actions generally reduce NMDA receptor sensitivity and/or transmission, and many of these agents increase GABA levels or transmission (Krystal et al. [@CR121]; Paul and Skolnick [@CR166]).

Elevated glutamatergic function is thought to support the neurophysiological activation of visceromotor circuits in depression. The anatomical projections between the MPFC, striatum and amygdala implicated in mood disorders are formed by predominantly excitatory projections in rats and monkeys (Ongür et al. [@CR162]; Ongür and Price [@CR163]). Since cerebral glucose metabolism largely reflects the energetic requirements associated with glutamatergic transmission (Shulman et al. [@CR202]), the elevated metabolism evident in limbic-thalamo-cortical circuits in depression implies that glutamatergic transmission is increased in these circuits (Drevets et al. [@CR67]; Swerdlow and Koob [@CR215]). During effective antidepressant drug or electroconvulsive therapy, metabolic activity decreases in these regions (Table [1](#Tab1){ref-type="table"}; reviewed in Drevets et al. [@CR54], [@CR56]), compatible with evidence that these treatments result in desensitization of NMDA receptors in the PFC (Paul and Skolnick [@CR166]). As described above, elevated glutamatergic transmission within discrete anatomical circuits also may explain the targeted nature of gray matter changes within mood disorders (e.g., affecting left more than right sgACC) (McEwen and Magarinos [@CR140]; Drevets and Price [@CR62]).

Magnetic resonance spectroscopic (MRS) studies of MDD also demonstrate abnormalities of glutamate (measured together with cerebral glutamine as the combined "Glx" peak in the MRS spectra) and GABA concentrations in MDD. These spectra reflect the combined intracellular and extracellular pools of glutamate, glutamine and GABA, but are dominated overwhelmingly by the intracellular pools. Depressed MDD subjects show abnormally reduced GABA levels in both, the dorsomedial/dorsal anterolateral PFC and the occipital cortex (Sanacora et al. [@CR191]; Hasler et al. [@CR101]). The majority of the GABA pool exists within GABAergic neurons, so the reduction in GABA in the dorsal anterolateral PFC is compatible with the report of reduced GABA-ergic neurons in this region (BA9) in MDD (Rajkowska et al. [@CR178]).

Depressed subjects also show abnormally reduced Glx levels in the dorsomedial/dorsal anterolateral and ventromedial PFC regions where histopathological and neurophysiological abnormalities are evident in depression (Drevets and Price [@CR62]). Since the Glx measure reflects the intracellular glutamate and glutamine pools, the abnormal reductions in Glx concentrations would be compatible with the reductions in glial cells found post mortem in the same regions in MDD, as glia play prominent roles in glutamate--glutamine cycling.

### Glucocorticoid system {#Sec9}

The hypothalamic-pituitary-adrenocortical (HPA) axis appears overactive in some patients with depression. Severe depression is associated with hypersecretion of cortisol, pituitary and adrenal gland enlargement, and CSF--CRF levels that are increased to an extent that is inappropriate to the plasma cortisol concentrations, implying that both deficits in negative feedback systems and/or excessive central stimulation of the secretion of CRF and/or other ACTH secretagogues exists in mood disorders (Gold and Chrousos [@CR89]; Drevets et al. [@CR56]; Swaab et al. [@CR214]; Carroll et al. [@CR28]). Depressed subjects also show blunted ACTH responses to CRF in vivo, and reduced CRF receptor density in the PFC and increased corticotrophic cell size and mRNA levels in the pituitary post mortem, indicating chronic activation of the HPA axis (Gold and Chrousos [@CR89]; Lopez et al. [@CR129]; Swaab et al. [@CR214]). Finally, some depressives show reduced sensitivity to glucocorticoid "fast feedback" (Young et al. [@CR239]) and/or to dexamethasone negative feedback (Carroll et al. [@CR29]), although these findings depend upon depressive subtype, being most common in melancholic and psychotic cases (Carroll et al. [@CR28]). During *successful* treatment, serum cortisol and CSF levels of CRF normalize, and cortisol secretion becomes suppressible by dexamethasone (Musselman and Nemeroff [@CR149]). The chronic elevation of cortisol secretion in some depressive subtypes is thought to contribute to mitochondrial dysfunction, neuropathological changes, elevated body temperature, premature osteoporosis and aging, and other medical morbidity in individuals suffering from mood disorders (McEwen and Magarinos [@CR140]; Gold et al. [@CR90]).

### Serotonergic system {#Sec10}

The central serotonin (5-HT) system has received particular attention in depression research because selective serotonin reuptake inhibitors (SSRI) exert antidepressant effects, and most other antidepressant drugs also increase 5-HT transmission. This effect of antidepressant drugs may augment an endogenous elevation of serotonin release during the stress associated with depression, analogous to the enhanced 5-HT transmission that occurs in some brain regions during stress in rodents (Cannon et al. [@CR24]; Barton et al. [@CR8]; Inoue et al. [@CR108]). Enhancement of 5-HT transmission in MDD also may compensate for the abnormalities in density and sensitivity of some 5-HT receptor subtypes evidenced by post mortem, neuroimaging and pharmacological challenge studies of depression (Stockmeier [@CR208]). For example, *postsynaptic* 5-HT~1A~ receptor binding or mRNA expression is decreased in the insula, cingulate, parieto-occipital and orbital/ventrolateral prefrontal cortices in most studies of MDD and BD (e.g., Drevets et al. [@CR55], [@CR65]; Sargent et al. [@CR194]; Lopez et al. [@CR128]), and the thermic and adrenocorticotropin/cortisol responses to 5-HT~1A~ receptor agonist challenge are blunted in MDD (Lesch [@CR126]). Conversely, chronic administration of antidepressant drugs with diverse primary pharmacological actions enhances post-synaptic 5-HT~1A~ receptor function (Haddjeri et al. [@CR98]; Chaput et al. [@CR32]). Compatible with hypotheses that enhancement of 5-HT transmission is relevant to maintaining remission in MDD, about one-half of remitted MDD subjects who are unmedicated or are being treated with SSRI agents experience depressive relapse under tryptophan depletion (which putatively decreases central serotonergic function; e.g., Neumeister et al. ([@CR155]).

It remains unclear whether the reduction in 5-HT~1A~ receptor function and expression in mood disorders constitutes a neurodevelopmental or an acquired abnormality. This issue is of interest because interruption of 5-HT~1A~ receptor function during neurodevelopment persistently alters the function of emotion modulating systems in genetically engineered mice (Gross et al. [@CR97]). Nevertheless, the reduction in 5-HT~1A~ receptor binding and mRNA expression in depression may arise secondarily to cortisol hypersecretion (Lopez et al. [@CR128]), as the 5-HT~1A~ receptor mRNA expression and density are under tonic inhibition by glucocorticoid receptor (GR) stimulation. In experimental animals the increased CORT secretion during chronic or repeated stress results in decreased 5-HT~1A~ receptor mRNA expression and density (Lopez et al. [@CR128]; Flugge [@CR77]). Moreover, the mood and anxiety disordered subgroups with reduced 5-HT~1A~ receptor binding appear limited to those who manifest evidence of a diathesis to hypersecrete cortisol (e.g., under stressed conditions) (Lopez et al. [@CR128]; Drevets et al. [@CR55], [@CR65]).

Altered serotonin transporter (5-HTT) function also is thought to play a role in the pathophysiology of MDE (Cannon et al. [@CR23]; Stockmeier [@CR208]). Multiple genetic polymorphisms involving 5-HTT regulatory sites reportedly increase the vulnerability for developing mood disorders (reviewed in Cannon et al. [@CR24]). For example, the common "short" allele of the functional 5-HTT LPR polymorphism increases the vulnerability for developing MDD within the context of stressful life events (Caspi et al. [@CR30]).

### Catecholaminergic systems {#Sec11}

The central dopaminergic and noradrenergic systems also have been implicated in the pathophysiology of depression and the mechanisms of antidepressant drugs (Nutt [@CR159]). Administration of reserpine or α-methyl-*para*-tyrosine, which reduces the availability of brain catecholamines, induces depressive syndromes in vulnerable individuals (e.g., Hasler et al. [@CR100]). Conversely, norepinephrine (NE) reuptake inhibitors, dopamine (DA) reuptake inhibitors (i.e., nomifensine) and dopamine receptor agonists (e.g., pramipexole) exert antidepressant effects in placebo-controlled studies (Willner [@CR238]; Zarate et al. [@CR240]). In MDD the CSF and jugular vein plasma levels of the DA metabolite, homovanillic acid, are abnormally decreased, consistent with decreased DA turnover (Willner [@CR238]; Lambert et al. [@CR123]). In contrast, the levels of NE metabolite concentrations were decreased in some (e.g., Lambert et al. [@CR123]), but increased in other studies (e.g., Veith et al. [@CR227]). Neuroimaging studies of MDD showed reduced striatal DA transporter binding and \[^11^C\][l]{.smallcaps}-DOPA uptake across the blood--brain-barrier, consistent with reduced DA neurotransmission (Nutt [@CR159]). Finally, degeneration of DA neurons in Parkinson's Disease is associated with increased vulnerability for developing a major depressive syndrome (Santamaria et al. [@CR192]).

The mesolimbic DA projections from the ventral tegmental area (VTA) to the nucleus accumbens shell and the medial PFC play major roles in learning associations between operant behaviors or sensory stimuli and reward, and in mediating the reinforcing properties of drugs of abuse and natural rewards such as food and sex (Nestler and Carlezon [@CR152]). Thus the evidence suggesting that DA release is reduced in depression gave rise to hypotheses that a reduction in mesolimbic DA function underlies the anhedonia, amotivation and psychomotor slowing associated with MDE (Swerdlow and Koob [@CR215]; Nestler and Carlezon [@CR152]). A preliminary study which used PET measures of \[C-11\]raclopride binding to DA D2/D3 receptors to assess endogenous DA release found that depressed subjects showed less DA release than healthy controls in response to monetary reward (Martin-Soelch and Drevets, unpublished data).

### Cholinergic system {#Sec12}

The cholinergic system is also implicated in the pathophysiology of mood disorders, with evidence indicating that the muscarinic cholinergic system is overactive or hyper-responsive in depression. Janowsky et al. ([@CR112]) reported that increasing cholinergic activity using the acetylcholine--esterase inhibitor physostigmine resulted in the rapid induction of depressive symptoms in currently manic bipolar subjects, and in a worsening of symptoms in unipolar depressed patients. In addition, depressed individuals express exaggerated polysomnographic, neuroendocrine and pupillary responses to cholinergic agonists or muscarinic receptor agonists relative to healthy controls (Dilsaver [@CR49]; Janowsky et al. [@CR113]; Janowsky and Overstreet [@CR111]; Rubin et al. [@CR186]; Riemann et al. [@CR182]), and aspects of sleep abnormalities observed in depression, including decreased REM latency and increased REM density (Gillin et al. [@CR88]), are thought to reflect hypersensitivity of muscarinic cholinergic receptors. Taken together, these data contribute to the hypothesis that a hyper-responsive cholinergic system may contribute to mood symptoms associated with mood disorders (Janowsky et al. [@CR112]).

The preclinical literature also implicates the muscarinic receptor system in mediating the cholinergic effects on emotional behavior. In a line of rats genetically bred for increased sensitivity of muscarinic receptors, the use of cholinergic agonists results in the enhancement of the behavioral analogs of depression, while the use of antimuscarinic drugs results in the improvement in these behaviors (Overstreet [@CR165]). Consistently, the muscarinic cholinergic receptor antagonist, scopolamine, exerts rapid and robust antidepressant effects in depressed MDD and BD patients (Furey and Drevets [@CR81]).

Several studies more specifically implicate the M~2~-receptor (M~2~R) in mood-regulation and depression. Multiple M~2~R gene polymorphisms were associated with increased risk for developing MDE (Comings et al. [@CR36]; Wang et al. [@CR234]). The administration of the M~2~R antagonist procaine elicits emotional responses in humans ranging from sadness, fear and severe anxiety, to euphoria, and results in increased physiological activity of the cingulate cortex (Ketter et al. [@CR117]; Benson et al. [@CR12]), a region densely innervated by cholinergic projections. Finally, decreased M~2~R binding has been reported in the cingulate cortex in bipolar depressives (Cannon et al. [@CR22]), using PET-neuroreceptor imaging (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Reduced muscarinic type 2 (M2) receptor binding in the cingulate cortex in depressed subjects with bipolar disorder relative to healthy controls. The statistical parametric map shows voxel *t* values corresponding to areas where the uptake of \[^18^F\]FP-TZTP, a PET radioligand which selectively binds M2 receptors, was significantly reduced (at *P* \< 0.005) in bipolar depressives relative to healthy controls. The areas of maximal difference between groups were located in the anterior cingulate cortex. Reproduced from Cannon et al. ([@CR22])

Cholinergic system dysfunction also may contribute to the subjective sense of impaired concentration and memory, as well as the objective findings of attentional biases in depression. Cholinergic neuromodulation influences multiple cognitive processes, such that cholinergic enhancement generally improves performance on memory and attention tasks (Bartus et al. [@CR9]; Peterson and Gibson [@CR168]) while blocking cholinergic activity impairs performance (Rusted and Warburton [@CR188]; Sitaram et al. [@CR206]). Acetylcholine is thought to act on neural processing through signal-to-noise (S/N) mechanisms (Murphy and Sillito [@CR147]; Sato et al. [@CR196]), and consistently researchers have demonstrated that boosting cholinergic activity increases the selectivity of neural response to target sensory stimuli (Furey et al. [@CR82]; Sillito and Kemp [@CR205]; Furey et al. [@CR83]). In this way, the cholinergic influence on S/N may represent the neural mechanism that underlies the cholinergic influence on attention. Moreover, acetylcholine modulates emotional processing, both in animals (McGaugh [@CR141]; Power and McGaugh [@CR171]) and in humans (Bentley et al. [@CR13]), and similarly may utilize S/N modulation for differential representations of emotional information.

Excessive cortical cholinergic activity in experimental animals results in "hyperattentive impairments" (Sarter et al. [@CR195]), where over activity of the cholinergic system reduces the signal detection threshold and leads to over processing of stimuli. Given the central role of ACh in emotional and sensory processing, the over-activity of the cholinergic system in mood disorders conceivably could alter S/N processing to produce an over-representation of emotionally laden information, creating the emotional processing bias and correlated cognitive deficits (see below).

Autonomic nervous system function in mood disorders {#Sec13}
---------------------------------------------------

Relative to nondepressed controls matched for cardiac disease, depressed patients show a two to fourfold increase in sudden death and a sevenfold increase in ventricular arrhythmia (Carney et al. [@CR27]). This excess risk of cardiac events in MDD is hypothesized to result partly from elevated noradrenergic and sympathetic autonomic function, coupled with reduced parasympathetic tone on the heart rate (HR) (Carney et al. [@CR27]).

Alterations of cognitive and emotional processing in mood disorders {#Sec14}
-------------------------------------------------------------------

Cognitive and neuropsychological impairments are characteristics of MDE, and are included in the diagnostic criteria for MDD as "an impaired ability to think or concentrate" (APA [@CR4]). Nonetheless, studies designed to characterize cognitive symptoms in patients with mood disorders have produced discrepant results. Some studies have reported wide-ranging deficits that include impairments in early information processing, attention, memory, and executive functions (Ottowitz et al. [@CR164]; Tavares et al. [@CR217]), while other studies failed to identify such deficits (Channon et al. [@CR31]; Grant et al. [@CR95]; Purcell et al. [@CR174]). Several factors likely contribute to the discrepancies in the literature, including heterogeneous patient groups, medication status, and differences in cognitive task paradigms that are presumed to assess the same cognitive domain. Despite these discrepancies, a sufficient amount of evidence points consistently to the presence of cognitive impairment in MDD and BD. Moreover, the existence of residual cognitive deficits in remitted patient groups demonstrates that some cognitive features occur independently of mood state (Clark et al. [@CR35]; Tham et al. [@CR219]).

### Early information processing {#Sec15}

Impairments in early information processing are evident in patients with mood disorders. Inspection time, which is measured as the minimum stimulus presentation time necessary for near perfect performance on a two-choice visual discrimination task, assesses the speed of early information processing independent of motor speed or cognitive strategy. Inspection time was reportedly longer in unmedicated MDD patients than in medicated MDD or in healthy controls (Tsourtos et al. [@CR223]). In a visual backward masking (VBM) task, where a stimulus is shown briefly and then "masked" or covered in space using a noninformative stimulus, *medicated* BD subjects had deficits in the identification of masked stimuli, consistent with an impairment early in the information processing pathway (Fleming and Green [@CR74]).

### Emotional processing bias {#Sec16}

A consistently reported finding in mood disorders is a mood-congruent processing bias, which is defined as a tendency to bias stimulus processing towards negative information as compared to positive or neutral information (Elliott et al. [@CR70]; Murphy et al. [@CR146]; Murray et al. [@CR148]). In memory studies, currently depressed patients have enhanced recall for negatively toned material as compared to positively toned information (Bradley et al. [@CR17]; Murray et al. [@CR148]). In the context of attention paradigms, depression-related negative words produce more interference on emotional stroop tasks than do happy or neutral words (Broomfield et al. [@CR21]; Gallardo Perez et al. [@CR84]). In an affective attention shifting task (i.e., affective go/no-go), *medicated* (Murphy et al. [@CR146]) and *unmedicated* (Erickson et al. [@CR73]) depressed subjects are faster when responding to the presentation of sad word as compared to happy word targets, a finding that is consistent with the idea that sad words are processed more readily. In a face dot-probe task designed to assess the allocation of attention between a face with a neutral expression and a face with an emotional expression, individuals with MDD consistently attend preferentially to faces with sad expressions (Gotlib et al. [@CR91], [@CR92]). Finally, *medicated* depressed patients are more negative in their interpretation of ambiguous words (Mogg et al. [@CR142]) and ambiguous situations (Nunn et al. [@CR158]) than are healthy participants. Together, these findings suggest that a bias in stimulus processing exists in patients with mood disorders that may produce a preferential representation of negatively toned information.

Functional neuroimaging studies have been used to assess the relation between processing biases and functional brain response in patients with mood disorders. Results are consistent with behavioral findings, showing altered neurophysiological responses in brain regions that process emotional information (detailed above) during tasks that utilize emotional stimuli. The amygdala shows elevated levels of activity in MDD during exposure to sad faces (Drevets et al. [@CR57]), a finding that has been replicated (Fu et al. [@CR80]). Similarly, increased activity in amygdala was observed during presentation of masked fearful (Sheline et al. [@CR200]) and masked sad faces (Fu et al. [@CR80]) in MDD patients versus healthy controls, and higher activity was seen in lateral orbital cortex following negative emotional stimuli in the affective go/no-go task (Elliott et al. [@CR71]). Similar increases in amygdala activity were observed in response to sad faces in remitted subjects with MDD (Neumeister et al. [@CR153]), suggesting that this abnormality is trait-like in an MDD subgroup. In another study, healthy volunteers showed a linear increase in activity bilaterally in fusiform visual cortex and ventral striatum as the intensity of a happy facial expression was increased, while MDD patents showed a similar pattern of increase in neural activity as the intensity of a sad expression was increased, but the response pattern in the patient group also extended into hippocampus and amygdala (Surguladze et al. [@CR213]). This literature suggests that neural responses within the neural circuits underlying emotional processing are altered, and that these altered responses may represent the neurophysiological correlates to the emotional processing bias observed in mood disorders.

### Attention, memory and learning {#Sec17}

Subjective impairments of concentration and attention are among the most commonly reported symptoms and sources of functional impairment associated with MDE. Although disagreement remains, standard measures of attention and memory that depend on traditional neuropsychological test batteries have failed to identify clear, consistent patterns of deficits in MDD and BD (Elliott et al. [@CR72]; Grant et al. [@CR95]; Purcell et al. [@CR174]; Ravnkilde et al. [@CR180]), and this likely is due partially to the lack of tasks designed specifically for this clinical population. Selective attention (without shifting set) and working memory (Landro et al. [@CR124]; Rose and Ebmeier [@CR184]; Stordal et al. [@CR210]) have been found to be impaired in depression, but these findings have not been found consistently (Purcell et al. [@CR174]), and the results are complicated further by the fact that most patients were medicated during study participation. Deficits in verbal memory have been identified in currently depressed subjects and in unaffected twins and non-twin siblings of BD subjects (Gourovitch et al. [@CR94]; Keri et al. [@CR115]; MacQueen et al. [@CR132]), raising the possibility that impaired verbal memory may constitute an endophenotype for BD. Impairments of spatial recognition memory and delayed matching to sample tasks also have been reported in *medicated* subjects with MDD and BD (reviewed in Taylor Tavares et al. [@CR218]), but such impairments generally have not been reported in *unmedicated* samples with MDD or BD (Grant et al. [@CR95]; Purcell et al. [@CR174]).

Implications for neurocircuitry models of depression {#Sec18}
====================================================

The neuropathological, neurophysiological and neurochemical abnormalities extant within the extended visceromotor network may impair this network's modulation of endocrine, autonomic, neurotransmitter, emotional and behavioral responses to aversive and reward-related stimuli or contexts (Ongür et al. [@CR162]), potentially accounting for the disturbances within these domains in mood disorders (Fig. [5](#Fig5){ref-type="fig"}). The abnormally increased CBF and metabolism in the orbital cortex, VLPFC, sgACC, pgACC, amygdala, ventral striatum, and medial thalamus evident in depression (Fig. [3](#Fig3){ref-type="fig"}) implicate a limbic-thalamo-cortical circuit involving the amygdala, the mediodorsal nucleus of the thalamus (MD) and the MPFC, and a limbic-striatal-pallidal-thalamic circuit involving related parts of the striatum and ventral pallidum along with the components of the other circuit (Drevets et al. [@CR67]). The first of these circuits can be conceptualized as an excitatory triangular circuit (Fig. [5](#Fig5){ref-type="fig"}) whereby the BLA and the MPFC are interconnected by excitatory (especially glutamatergic) projections with each other and with the MD (Amaral and Price [@CR3]; Amaral and Insausti [@CR2]; Bacon et al. [@CR6]; Kuroda and Price [@CR122]; Jackson and Moghaddam [@CR110]), so increased glucose metabolism in these structures would presumably reflect increased synaptic transmission through the limbic-thalamo-cortical circuit. The limbic-striatal-pallidal-thalamic circuit constitutes a disinhibitory side loop between the amygdala or PFC and the MD. The amygdala and the PFC send excitatory projections to overlapping parts of the ventromedial striatum (Russchen et al. [@CR187]). This part of the striatum sends an inhibitory projection to the ventral pallidum (Graybiel [@CR96]) which in turn sends GABA-ergic, inhibitory fibers to the MD (Kuroda and Price [@CR122]). Because the pallidal neurons have relatively high spontaneous firing rates (DeLong [@CR46]), activity in the PFC or amygdala that activates the striatum and in turn inhibits the ventral pallidum may release the MD from the inhibitory pallidal influence, potentially disinhibiting transmission through the limbic-thalamo-cortical circuitry. Notably, repeated stress results in hyperexcitability states in the BLA in rodents, although whether the mechanisms underlying these changes involve changes in afferent modulation of the amygdala or alterations in synaptic plasticity have not been established (Shekhar et al. [@CR199]; Vyas et al. [@CR231]).Fig. 5Anatomical circuits involving the medial PFC (MPFC) and amygdala reviewed within the context of a model in which MPFC dysfunction results in disinhibition of limbic transmission through the amygdala, yielding the emotional, cognitive, endocrine, autonomic and neurochemical manifestations of depression. The basolateral amygdala sends efferent projections to the central nucleus of the amygdala (*ACe*) and the bed nucleus of the stria terminalis (*BNST*). The efferent projections from these structures to the hypothalamus, periaqueductal gray (*PAG*), nucleus basalis, locus ceruleus, raphe and other diencencephalic and brainstem nuclei then organize the neuroendocrine, neurotransmitter, autonomic, and behavioral responses to stressors and emotional stimuli (Davis and Shi [@CR45]; LeDoux [@CR125]). The MPFC shares reciprocal projections with all of these structures (although only the connections with the amygdala are illustrated) which function to modulate each component of emotional expression (Ongür et al. [@CR162]). Impaired MPFC function thus may disinhibit or dysregulate limbic outflow through the ACe and BNST. *Solid white lines* indicate some of the major anatomical connections between structures, with *closed arrowheads* indicating the direction of projecting axons. *Solid yellow lines* show efferent pathways of the ACe and BNST, which generally are monosynaptic, but in some cases are bisynaptic connections (e.g., Herman and Cullinan [@CR103]). Other abbreviations: *5-HT* serotonin, *ACh* acetylcholine, *DA* dopamine, *DL* dorsolateral column of PAG; *N* nucleus, *NE* norepinephrine, *NTS* nucleus tractus solitarius, *PVN* paraventricular N of the hypothalamus, *VL* ventrolateral column of PAG, *VTA* ventral tegmental area. Reproduced from Drevets ([@CR53])

The BLA sends anatomical projections to the central nucleus of the amygdala (ACe) and the BNST, and projections from these structures to the hypothalamus, PAG, nucleus basalis, locus ceruleus, raphe and other diencencephalic and brainstem nuclei play major roles in organizing the neuroendocrine, neurotransmitter, autonomic, and behavioral responses to stressors and emotional stimuli (Davis and Shi [@CR45]; LeDoux [@CR125]). The MPFC sends overlapping projections to each of these structures as well as to the amygdala which function to modulate each component of emotional expression (Ongür et al. [@CR162]). The neuropathological changes evident in the MPFC in primary and some secondary mood disorders thus may impair the modulatory role of the MPFC over emotional expression, disinhibiting or dysregulating limbic responses to stressors and emotional stimuli.

Reciprocal functional relationships between the cortical (e.g., MPFC) and limbic (e.g., amygdala) structures that modulate or mediate emotional expression have been demonstrated by electrophysiological and lesion analysis studies in experimental animals. In rats stimulation of projections from the amygdala to the mPFC inhibits neuronal ensemble activity in the mPFC, and stimulation of projections from the mPFC to the amygdala excites intra-amygdaloid GABA-ergic cells that *inhibit* neuronal activity in the ACe (Likhtik et al. [@CR127]; Perez-Jaranay and Vives [@CR167]). Moreover, rats exposed to fear-conditioned stimuli show reduced mPFC neuronal firing activity, and the magnitude of this decrement correlates inversely with the corresponding increase in amygdala neuron activity and fear behavior (Garcia et al. [@CR85]). Conversely, lesions of the right or bilateral mPFC enhance behavioral, sympathetic, and endocrine responses to stressors or fear-conditioned stimuli in rats (Morgan and LeDoux [@CR144]; Sullivan and Gratton [@CR212]).

Reciprocal relationships between the effects of MPFC and amygdala function on emotional behavior also are evident in humans. In MDD depression severity correlates positively with amygdala and sgACC activity, but negatively with activity in the left VLPFC/lateral orbital cortex (Drevets et al. [@CR56]). Lesions of the left orbital cortex increase the risk for developing depression (MacFall et al. [@CR131]), whereas electrical stimulation of the amygdala can produce fear, anxiety, dysphoria, sympathetic autonomic arousal, social withdrawal and cortisol release in humans and/or nonhuman primates (reviewed in Drevets [@CR51]). Drugs and deep brain stimulation that exerts antidepressant effects in MDD show a common effect of reducing physiological activity in the amygdala and/or sgACC, despite having diverse primary actions in the brain (Drevets et al. [@CR54]; Mayberg et al. [@CR138]; Van Laere et al. [@CR226]). In contrast, a preliminary study found that interpersonal psychotherapy, which also can reduce depressive symptoms in MDD, enhances activity in the VLPFC/anterior insula (Brody et al. [@CR19]). Finally, *higher activity* in the pgACC holds *positive prognostic significance* in MDD*,* as depressives who improve during antidepressant treatment show higher pgACC metabolism and electrophysiological activity than treatment-nonresponsive cases and healthy controls (Mayberg et al. [@CR136]; Pizzagalli et al. [@CR170]). Taken together, these data suggest that during depressive episodes the increased activity seen within some MPFC areas reflects a compensatory response which modulates depressive symptoms, and impaired function of these regions (possibly due to the neuropathological changes described above) results in more severe and treatment-refractory illness.

An impairment of MPFC function that disinhibits amygdala activity also may contribute to the neuroendocrine, autonomic, neurotransmitter, attention and reward-seeking abnormalities associated with MDE (Fig. [5](#Fig5){ref-type="fig"}). The amygdala mediates the *stressed component* of glucocorticoid hormone secretion by disinhibiting CRF release from the hypothalamic paraventricular nucleus (Herman and Cullinan [@CR103]). Conversely, the glucocorticoid response to stress is inhibited by stimulation of glucocorticoid receptor (GR) concentrations in the ventral ACC, such that lesioning this cortex in rats increases ACTH and CORT secretion during stress (Diorio et al. [@CR50]). Excessive amygdala activity combined with reduced ventral ACC gray matter thus conceivably may contribute to the excessive cortisol response to stress seen in depressed humans (Drevets et al. [@CR60]; McEwen and Magarinos [@CR140]; Gold et al. [@CR90]).

The autonomic imbalance associated with depression also could reflect MPFC dysfunction coupled with excessive amygdala activity. Amygdala stimulation of the locus ceruleus, lateral hypothalamus and PAG increases sympathetic autonomic arousal in rodents (Fig. [5](#Fig5){ref-type="fig"}) (LeDoux [@CR125]; Gold and Chrousos [@CR89]). In contrast the parasympathetic tone on the heart-rate is partly regulated by projections from the infralimbic cortex (which putatively forms the posterior segment of the human sgACC) to the nucleus tractus solitarius of the vagus nerve, and lesions of this cortex reduce the parasympathetic tone on the heart in rats (Frysztak and Neafsey [@CR79]). The effects of increased amygdala activity and reduced infralimbic cortex function conceivably could account for the increased ratio of sympathetic-to-parasympathetic tone on the heart rate seen in depression (Carney et al. [@CR27]).

Dysfunction of the MPFC coupled with amygdala hyperactivity also may contribute to the anhedonia, amotivation and inattention manifest in depression. The ACC receives extensive dopaminergic innervation from the VTA, and sends projections to the VTA that regulate phasic DA release. In rats, stimulation of these ventral ACC areas elicits burst firing patterns in the VTA-DA neurons, while inactivation of the ventral ACC converts burst firing patterns to pacemaker-like firing activity (Drevets et al. [@CR59]; Murase et al. [@CR145]; Taber and Fibiger [@CR216]; Gariano and Groves [@CR86]). The burst firing patterns increase DA release in the accumbens, which appears to encode information regarding reward prediction in monkeys (Schultz et al. [@CR198]). If the neuropathological changes extant within the ventral ACC in mood disorders interfere with its drive on VTA-DA neuronal burst firing activity they may impair reward *perception*, conceivably seen as a loss of the pleasure and behavioral reinforcement derived from normally rewarding activities.

In addition, the cognitive and behavioral response patterns supporting goal- or reward-directed activity are thought to depend upon PFC inputs to the ventral striatum, which are maintained or "gated" by projections from the hippocampal subiculum to the ventral striatum (Goto and Grace [@CR93]). Stimulation of projections from the amygdala to the ventral striatum interrupts the maintenance of these cortically driven response patterns, providing an adaptive, limbic override that interrupts goal-directed thought or behavior in response to unexpected threats or novelty. Nevertheless, in MDE the excessive amygdala activity conceivably could interfere with cognitive performance and goal directed behavior to an extent that is maladaptive.

Antidepressant treatment effects {#Sec19}
--------------------------------

Considering the effects of antidepressant treatments on circuitry-based models may elucidate common neurophysiological mechanisms that underlie their therapeutic benefits, despite the diversity of their primary actions in the brain. For example, somatic antidepressant therapies of various types modulate the activity in the amygdala, potentially reducing the efferent transmission from the central nucleus of the amygdala hypothesized to mediate depressive symptoms in the model shown in Fig. [5](#Fig5){ref-type="fig"}. Moreover, neurophysiological activity in the amygdala decreases in rats, monkeys and/or humans during administration of treatments that show antidepressant efficacy, including drugs, vagal nerve stimulation or deep brain stimulation of the anterior capsule (Drevets et al. [@CR54]; Sheline et al. [@CR200]; Fu et al. [@CR80]; Van Laere et al. [@CR226]; Gerber et al. [@CR87]; Henry et al. [@CR102]). Notably in rats (Horovitz [@CR106]) observed that direct injection of antidepressant drugs (AD) into and specific lesions of the central nucleus of the amygdala produced identical effects in animal models used to predict AD efficacy. In addition, metabolism and flow decrease in depressed humans in the sgACC/ventromedial PFC in response to chronic treatment with antidepressant drugs, vagus nerve stimulation or deep brain stimulation of the sgACC or anterior capsule (Mayberg et al. [@CR138]; Drevets et al. [@CR54]; Van Laere et al. [@CR226]; Mayberg et al. [@CR137]; Nahas et al. [@CR150]; Conway et al. [@CR38]).

In considering broader networks, activity in the limbic-thalamo-cortical circuitry decreases during effective treatment (Drevets et al. [@CR54]; Drevets et al. [@CR56]). The cortical areas implicated include the orbital cortex, ventrolateral PFC, and/or anterior insula, where many studies report that flow or metabolism decrease during treatment with antidepressant drugs or electroconvulsive therapy (e.g., Brody et al. [@CR20]; Drevets [@CR63]; Mayberg et al. [@CR137]; Nobler et al. [@CR156]). These areas show complex relationships between depression severity and physiological activity. While CBF and metabolism increase in these areas in the depressed relative to the remitted phases of MDD, the magnitude of these measures correlates inversely with ratings of depression severity (Drevets et al. [@CR67]). An inverse relationship between posterior orbital cortex activity and the intensity of emotional experience also is evident during anxiety provocation in subjects with obsessive--complusive disorder and induced sadness in healthy humans (Rauch et al. [@CR179]; Schneider et al. [@CR197]). These data appear consistent with electrophysiological data showing that parts of the orbital cortex participate in modulating behavioral and visceral responses associated with defensive, fear, and reward-directed behavior (Timms [@CR221]; Rolls [@CR183]), and that cerebrovascular lesions of the frontal lobe (Starkstein and Robinson [@CR207]) or more specifically the orbitofrontal cortex (MacFall et al. [@CR131]) increase the risk for developing major depression. Activation of the orbital cortex during depression thus may reflect compensatory attempts to modulate emotional expression or interrupt unreinforced aversive thought and emotion. If so, then reducing CBF and metabolism in the orbital cortex and ventrolateral PFC during antidepressant drug treatment and electroconvulsive therapy may not constitute a primary mechanism for ameliorating depressive symptoms. Instead, direct inhibition of pathological limbic activity in areas such as the amygdala and sgACC may be more essential to correcting the pathophysiology associated with mediating depressive symptoms, and the reduction in orbital cortex/VLPFC activity may reflect a secondary relaxation of these areas, once they are no longer recruited to modulate pathological limbic activity.

Finally, preliminary reports observe that chronic SSRI treatment or deep brain stimulation of the anterior capsule additionally reduces the abnormally elevated metabolism in the accumbens area in depression (Drevets et al. [@CR58]) or in depression associated with obsessive--complusive disorder (Van Laere et al. [@CR226]), and that deep brain stimulation applied via electrodes situated in the accumbens area/ventral internal capsule reportedly improves depressive symptoms in treatment-refractory depression (Schlaepfer et al. [@CR246]). Taken together, these data suggest the importance of modulating activity within the limbic-striatal-pallidal-thalamic circuitry in the treatment of depression.

Cognitive-behavioral strategies for managing depressive symptoms may instead rely upon enhancing the function of PFC systems that modulate limbic activity, thereby enhancing the normal role of cortico-limbic circuits in modulating emotional expression and experience (Siegle et al. [@CR203]). For example, interpersonal psychotherapy can reduce depressive symptoms in MDD, and has been shown to enhance activity in the VLPFC/anterior insula (Brody et al. [@CR19]).

Summary {#Sec20}
=======

Convergent results from studies conducted using neuroimaging, lesion analysis and post mortem techniques support models in which the signs and symptoms of depression emanate from dysfunction within an extended visceromotor network, which interferes with this system's modulation of emotional behavior. We have proposed more specifically that the effects of impaired function in and between the MPFC and related limbic structures can account for the disturbances of emotional processing, cognitive performance, neurotransmission, autonomic regulation and neuroendocrine responses that are associated with mood disorders. Somatic antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity which putatively mediates depressive symptoms (Drevets et al. [@CR54]) and the expression of neurotrophic/neuroprotective factors that preserve the function of the MPFC (Manji et al. [@CR133]). Cognitive-behavioral strategies for managing depressive symptoms may instead rely upon enhancing the function of these MPFC systems, thereby enhancing the normal role of cortico-limbic circuits in modulating emotional processing and experience.
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